Furthermore, since MT-RTKs are detectable in a variety of malignancies such as lung cancer with MT-EGFR, hepatocellular carcinoma with MT-MET, and gastric cancer with MT fibroblast growth factor receptor, the findings reported here can be further extended to other malignancies. This evidence concerns the gene MET and lung carcinoma.